Analyst Coverage
Disclaimer: Any opinions, estimates or forecasts regarding ResApp Health Limited’s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of ResApp Health Limited or its management. ResApp Health Limited does not by its reference to any analysts imply its endorsement of or concurrence with such information, conclusions or recommendations.
| Morgans Financial | August 28, 2019 | CE mark for children’s diagnostic a RAP |
| Bioshares | August 26, 2019 | ResApp Gains First Regulatory Clearance for Pediatric Diagnostic |
| Morgans Financial | July 31, 2019 | Critical six months ahead |
| Morgans Financial | April 30, 2019 | Plenty ahead to maintain momentum |
| Morgans Financial | April 23, 2019 | Breathe Easy delivers |
| Bioshares | April 1, 2019 | ResApp Reports Updated Results from US Pediatric Study |
| Morgans Financial | March 18, 2019 | Croup too rare to show significance |
| Morgans Financial | February 28, 2019 | Focus remains on study results |
| Bioshares | February 11, 2019 | Q3 FDA Filing for ResAppDx |
| Morgans Financial | January 3, 2019 | Short term catalysts to play |
| Morgans Financial | November 1, 2018 | Over reaction |
| Morgans Financial | September 3, 2018 | Big RAPs |
| Morgans Financial | August 2, 2018 | Key catalyst imminent |
| Bioshares | July 16, 2018 | ResApp to Report Outcomes from Multiple Trials in Coming Months |
| Morgans Financial | May 9, 2018 | Key results approach |
| Morgans Financial | March 1, 2018 | Focused on trial results in 3QCY18 |
| Morgans Financial | January 8, 2018 | Key milestone achieved with trial start |
| Bioshares | September 18, 2017 | ResApp Tightens Up Study Protocol for Repeat US Study |
| Morgans Financial | September 1, 2017 | Waiting for trial restart |
| Bioshares | August 11, 2017 | Learnings for ResApp from US Pediatric Study |
| Morgans Financial | August 9, 2017 | Endpoints not met |
| Morgans Financial | July 7, 2017 | What’s in a cough |
| NDF Research | June 30, 2017 | First major clinical study of ResAppDx reports important data |
| Patersons Securities | June 9, 2017 | Market Update |
| Patersons Securities | March 1, 2017 | 1H17 Result, Waiting on FDA Trial Data |
| Patersons Securities | November 16, 2016 | Initiating Coverage |
| Bioshares | August 19, 2016 | Telemedicine Adoption Building |
| NDF Research | July 25, 2016 | Initiation of Coverage |
| DJ Carmichael | April 4, 2016 | Emerging ASX Technology Sector |
| DJ Carmichael | October 19, 2015 | Emerging ASX Technology Sector |
| Bioshares | October 9, 2015 | Good Early Data for ResApp |
| Bioshares | August 28, 2015 | TeleMedicine is on the Move |
ResApp Health Limited
ABN 51 094 468 318
Headquarters: Level 8, 127 Creek St, Brisbane, QLD 4000
Registered Office: Level 24, 44 St Georges Tce, Perth, WA 6000
CONTACT US
+61 8 6211 5099
+61 8 9218 8875
General Information
Clinical Studies
Investor Relations
LEGAL
Terms of Use
Privacy Policy
ResAppDx-US is pending review of a request for De Novo classification and is not available for sale in the United States.
© 2019 ResApp Health Limited. All rights reserved. US Patent No. 10,098,569, Australian Patent No. 2013239327, Japanese Patent No. 6,435,257 and Patents Pending. ResApp Health®, the ResApp Health logo and ResAppDx® are registered trademarks of ResApp Health Limited in the United States and other countries.